View as a web page
From one to many: The cure agenda for HIV/AIDS at Fred Hutch
Join us Defeat HIV Timothy Ray Brown Foundation World Aids Institute
Scientific Forum

HIV Cure Research in Seattle – the Underlying Science
and Clinical Studies

Tuesday, June 18, 2013
11 a.m. - 4 p.m.

Fred Hutchinson Cancer Research Center
Weintraub Building – Pelton Auditorium
1100 Fairview Avenue N., Seattle, WA 98109

Deadline June 13

Timothy Brown
   Timothy Ray Brown

Timothy Ray Brown (“The Berlin Patient”) is thought to be the only individual functionally cured of HIV. Through a combination of chemotherapy followed by transplantation of HIV-resistant hematopoietic cells, his clinicians provided an important proof of concept that the latent reservoirs of HIV can be eradicated using nontraditional methods. On behalf of the HIV-affected community, he currently serves as an advocate for HIV cure efforts performed by researchers and clinicians across the globe.

This forum will present scientific data from defeatHIV
researchers including Fred Hutch’s Drs. Keith Jerome and
Hans-Peter Kiem, and industry partners and collaborators
actively involved in HIV cure efforts on how progress in the lab
is being translated into clinical studies. Timothy Ray Brown
also will be participating in the day’s agenda.

Refreshments and light lunch buffet will be provided.

RSVP Now »



11:00 - 11:15 am
Keith R. Jerome, M.D., Ph.D.
Fred Hutchinson Cancer Research Center
Welcome & Introduction – defeatHIV: program overview
Martin Delaney Collaboratories

11:15 - 11:25 am
Hans-Peter Kiem, M.D., FACP
Fred Hutchinson Cancer Research Center
defeatHIV: How Timothy Ray Brown was cured of HIV with a stem cell transplant

11:25 - 11:30 am
Timothy Ray Brown
In support of HIV Cure Research

11:30 - 11:55 am
Hans-Peter Kiem, M.D., FACP
Stem cell gene therapy for HIV/AIDS

11:55 - 12:25 pm
Keith Jerome, M.D., Ph.D.
HIV Targeting

12:30 - 1:30 pm

1:25 - 1:50 pm
Andy Scharenberg, M.D.
Seattle Children’s Research Institute
Expanding the repertoire and utility of targeted rare-cutting endonucleases

Alexander Astrakhan, Ph.D.
Hybrid Nucleases for Highly Efficient Generation of CCR5-disrupted T cells

1:55 - 2:20 pm
Winson Tang, M.D.
Sangamo BioSciences
defeatHIV Industry Partner

2:20 - 2:35 pm

2:35 – 3:00 pm
Jim Mullins, Ph.D.
Professor of Microbiology and of Medicine, UW
HIV Reservoirs

3:00 - 3:25 pm
Ann Wollfrey, M.D.
Fred Hutchinson Cancer Research Center
Hematopoietic Cell Transplant: Platform for Purging the Latent HIV Reservoir

3:25 - 3:50 pm
Julie McElrath, M.D., Ph.D.
Fred Hutchinson Cancer Research Center
Immune modulation as an adjunct to curative therapies

3:55 pm

Video Streaming

Unable to attend? Watch it online.


Social Media
Contribute to the discussion on Twitter at #defeatHIV.
Join the Facebook event.
Like Fred Hutch on Facebook.
Follow us on Twitter.

In collaboration with defeatHIV institutions:

Fred Hutchinson Cancer Research Center
University of Washington
Seattle Children’s
Beckman Research Institute of City of Hope
Sangamo BioSciences
National Institutes of Health

Sponsored by:
CFAR Curative Therapies for HIV Scientific Working Group
Sangamo BioSciences

About defeatHIV:
defeatHIV, the Delaney Cell and Genome Engineering Initiative, is one of three Martin Delaney Collaboratories funded by the National Institutes of Health to develop curative HIV therapies. Based at the Fred Hutchinson Cancer Research Center in Seattle, defeatHIV is comprised of scientific investigators and clinicians, from both public and private research organizations, who are committed to finding a cure for HIV.  For more information, please visit